ConductScience.org, home

Paper42465751

Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.

Kudriavskii VV and 3 others. Front Immunol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets. Papers, record 42465751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42465751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.
PubMed
Journal
Front Immunol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kudriavskii VVViacheslav V
2Koss VAValeriia A
3Shender VOVictoria O
4Arapidi GPGeorgij P

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Antigens, NeoplasmMajor topic
ImmunotherapyMajor topic
Humans
Animals
Epitopes
Alternative Splicing

Source PubMed

Download CSV of topics

References184

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131278396Alternative tumour-specific antigens.Nat Rev Cancer2019https://conductscience.org/library/papers/31278396PubMed
235904353Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.Cancer Res2022https://conductscience.org/library/papers/35904353PubMed
336735774Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer.Sci Immunol2023https://conductscience.org/library/papers/36735774PubMed
433328638Anti-tumour immunity induces aberrant peptide presentation in melanoma.Nature2021https://conductscience.org/library/papers/33328638PubMed
540866359Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells.Nat Commun2025https://conductscience.org/library/papers/40866359PubMed
639578174Generation of tumor neoantigens by RNA splicing perturbation.Trends Cancer2025https://conductscience.org/library/papers/39578174PubMed
738759626Arginine deprivation enriches lung cancer proteomes with cysteine by inducing arginine-to-cysteine substitutants.Mol Cell2024https://conductscience.org/library/papers/38759626PubMed
835264796Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.Nature2022https://conductscience.org/library/papers/35264796PubMed
937254712Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.Adv Sci (Weinh)2023https://conductscience.org/library/papers/37254712PubMed
1040756430Properties of CD8 T-cell-recognized neoantigens in different tumor types.Immunooncol Technol2025https://conductscience.org/library/papers/40756430PubMed
1128198830'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.Nat Immunol2017https://conductscience.org/library/papers/28198830PubMed
1238538867A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.Nat Med2024https://conductscience.org/library/papers/38538867PubMed
1338600345The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.EMBO Rep2024https://conductscience.org/library/papers/38600345PubMed
1439588782Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer.Nucleic Acids Res2024https://conductscience.org/library/papers/39588782PubMed
1533363023Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.Front Oncol2020https://conductscience.org/library/papers/33363023PubMed
1632866021Proteome-Wide Analysis of ADAR-Mediated Messenger RNA Editing during Fruit Fly Ontogeny.J Proteome Res2020https://conductscience.org/library/papers/32866021PubMed
1718806759E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35.Cell Death Differ2008https://conductscience.org/library/papers/18806759PubMed
1834297039ADAR and hnRNPC deficiency synergize in activating endogenous dsRNA-induced type I IFN responses.J Exp Med2021https://conductscience.org/library/papers/34297039PubMed
1942086309Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma.J Immunother Cancer2026https://conductscience.org/library/papers/42086309PubMed
2038506710Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.Clin Cancer Res2024https://conductscience.org/library/papers/38506710PubMed

See all 184 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42465751

GET https://conductscience.org/api/papers/v1/42465751/references?page=2